13G Filing: Nantahala Capital Management and Aeglea Bio Therapeutics Inc (AGLE)

Page 4 of 7 – SEC Filing

 

CUSIP NO.  00773J103 Page
4 of 7 Pages

 

CUSIP No.  00773J103
(1) Names of reporting persons Daniel Mack
(2) Check the appropriate box if a member of a group (a)  ¨
(see instructions) (b)  ¨
(3) SEC use only
(4) Citizenship or place of organization USA
Number of shares beneficially owned by each reporting person with:
(5) Sole voting power 0
(6) Shared voting power 1,813,573
(7) Sole dispositive power 0
(8) Shared dispositive power 1,813,573
(9) Aggregate amount beneficially owned by each reporting person 1,813,573
(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  ¨
(11) Percent of class represented by amount in Row (9) 10.9%
(12) Type of reporting person (see instructions) HC

 

Item 1(a). Name of Issuer:
AEGLEA BIOTHERAPEUTICS, INC. (the “Issuer”).
Item 1(b). Address of the Issuer’s Principal Executive Offices:
901 S. MoPac Expressway, Barton Oaks Plaza One, Suite 250, Austin, TX 78746
Item 2(a). Name of Person Filing

Nantahala Capital Management, LLC (“Nantahala”)

Wilmot B. Harkey

Daniel Mack (together the “Reporting Persons”)

Item 2(b). Address of Principal Business Office or, if None, Residence:

19 Old Kings Highway S, Suite 200

Darien, CT 06820

Item 2(c). Citizenship:

Nantahala is a Massachusetts limited liability company.

Each of Messrs. Harkey and Mack is a citizen of the United States
of America.

Item 2(d).

Title of Class of Securities:

 

Common Stock, $.0001 par value (the “Shares”).

Follow Spyre Therapeutics Inc. (NASDAQ:SYRE)